Cite
HARVARD Citation
Hierro, C. et al. (n.d.). 92PVall d'Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI). Annals of oncology. p. . [Online].